Metir's Qatar project targets October handover and recurring revenue

What has Metir announced?

Metir has received a Project Confirmation Letter from Avanceon Automation & Control concerning the company's Continuous Toxicity Monitoring project in Qatar.

The letter followed a meeting on 20 July 2026 involving Metir's Modern Water division, Avanceon and Qatar General Electricity & Water Corporation, known as Kahramaa.

It confirms the stakeholders' intention to continue the project, complete the delayed Phase 1 handover and potentially expand the installation through a second phase.

The immediate target is now final handover in October 2026. Reaching that milestone should release outstanding project payments and move the contract into its maintenance phase, when Metir expects to begin earning recurring revenue from consumables.

The key figures

Item	Detail
Existing CTM systems	27
Revised Phase 1 handover	October 2026
Outstanding milestone payment	Approximately £161,000
Additional performance payment	Approximately £44,000
Expected monthly consumables revenue after handover	Around £30,000
Potential additional Phase 2 systems	17
Potential total installed systems	44
Potential monthly reagent revenue after Phase 2	More than £50,000
Intended project duration	At least 10 years
Reagent replacement cycle	30 days

The two payments connected with the Phase 1 milestone amount to approximately £205,000 in total. However, the October handover must be completed before the outstanding milestone payment can be released and the performance payment invoiced.

Why the maintenance phase matters

The investment case within this announcement is less about supplying the initial equipment and more about what happens afterwards.

Following final handover, Metir expects to invoice monthly for Microtox reagent and other consumables used by all 27 installed systems. Consumables are products that need to be replaced regularly as the equipment operates.

Metir describes these revenues as high margin and expects the current installed base to generate around £30,000 per month. On a simple annualised basis, that would equal approximately £360,000, assuming the monthly run rate is maintained for a full year.

This revenue has not started yet. It depends on the final project handover taking place, which Kahramaa currently expects in October 2026.

Nevertheless, the move towards repeat monthly sales could make the project's revenue profile more predictable than one-off equipment deliveries. The intended project duration of at least 10 years also points towards a potentially long commercial relationship, although the announcement does not disclose contractual minimum revenue commitments over that period.

Phase 2 offers meaningful upside, but it is not secured

The letter also records an intention to begin a Phase 2 tender process covering another 17 CTM systems. If awarded and installed, this would increase the Qatar deployment from 27 to 44 machines.

Metir says monthly reagent revenue from 44 systems is likely to exceed £50,000. That represents an annualised run rate of more than £600,000, before considering any equipment revenue associated with supplying the additional units.

There is an important qualification. Phase 2 remains subject to standard procurement and tender procedures. Metir has not yet won that work, and no tender timetable, equipment contract value or expected profit contribution has been disclosed.

Investors should therefore view Phase 2 as a commercial opportunity rather than contracted revenue.

What caused the handover delay?

The project has faced operational disruption from regional hostilities, which have constrained bio-reagent shipments to Qatar and limited the ability of Modern Water personnel to travel to Doha.

These restrictions delayed the operational testing needed for final handover. Metir also says some installation issues previously announced on 25 March 2026 still need to be resolved.

Encouragingly, the company's review found no material instrument problems across the 27 deployed CTM systems. Instead, the main difficulties relate to the local storage, transportation, handling and performance of the Microtox reagent in high ambient temperatures.

Some reagents did not last for their prescribed monthly working cycle, resulting in interruptions to CTM operations. Metir and Avanceon have now introduced an updated storage, handling and device maintenance programme adapted to local conditions.

A specialist biochemist is also due to travel to Doha to support on-site optimisation, validate the revised processes and oversee the final handover milestone.

This distinction matters. Problems with consumable handling may be more manageable than fundamental faults across the installed equipment base. Even so, the revised October date still depends on the optimisation work succeeding under challenging regional conditions.

Local reagent production could improve resilience

The project stakeholders have expressed support for establishing a laboratory facility in Doha to produce Microtox reagent locally.

In principle, local production could reduce the shipping and transportation difficulties that contributed to the current delays. It could also help Metir adapt reagent supply and handling more closely to Qatar's environmental conditions.

However, the announcement does not confirm that the laboratory has been approved, financed or commissioned. Its cost, ownership structure, capacity and opening date are also not disclosed.

For now, it is best treated as a proposed solution that could improve the project's operational resilience rather than a completed investment.

What does the technology do?

Microtox CTM provides automated, real-time toxicity monitoring. It continuously samples and tests water, issuing alerts within minutes when potential contamination is detected.

The system is designed as a broad first line of defence rather than a test for only one contaminant. Metir says it is capable of screening for thousands of toxins and can provide continuous 24-hour early-warning monitoring for public water supplies and industrial operations.

Modern Water is the sole supplier of this CTM technology, meaning an expanded installation should also increase demand for Metir's associated reagents and consumables.

The investor positives and risks

The strongest positive is that the Qatar stakeholders have confirmed their intention to continue the project after a period of uncertainty. The existing 27 machines have no material instrument problems, a revised handover date has been established and Metir can see a route towards approximately £30,000 of monthly recurring revenue.

The project could also become a useful commercial reference for future CTM opportunities in the Middle East. That is the Board's view, although no additional regional contracts have been disclosed.

The risks remain clear. Phase 1 has not yet reached final handover, reagent performance needs further validation and regional hostilities continue to affect travel and logistics. The £205,000 of milestone and performance payments is not yet fully secured as cash, while Phase 2 remains dependent on a competitive tender process.

October is the key delivery test

This update reduces some of the uncertainty surrounding Metir's Qatar project, but it does not remove execution risk.

The next major test is whether Modern Water and Avanceon can complete optimisation and achieve final handover in October 2026. Success would unlock the remaining Phase 1 payments and, more importantly, start the recurring consumables revenue attached to the 27 installed systems.

After that, investor attention can turn towards the consistency of reagent sales, progress on local production and whether the proposed 17-system Phase 2 expansion converts into a firm order.